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Sjögren’s syndrome (SS) is a chronic autoimmune epithelitis that combines exocrine
gland dysfunctions and lymphocytic inﬁltrations. While the pathogenesis of SS remains
unclear, its etiology is multifunctional and includes a combination of genetic predis-
positions, environmental factors, and epigenetic factors. Recently, interest has grown
in the involvement of epigenetics in autoimmune diseases. Epigenetics is deﬁned as
changes in gene expression, that are inheritable and that do not entail changes in
the DNA sequence. In SS, several epigenetic mechanisms are defective including DNA
demethylation that predominates in epithelial cells, an abnormal expression of microRNAs,
and abnormal chromatin positioning-associated with autoantibody production. Last but not
least, epigenetic modiﬁcations are reversible as observed in minor salivary glands from
SS patients after B cell depletion using rituximab. Thus epigenetic ﬁndings in SS open
new perspectives for therapeutic approaches as well as the possible identiﬁcation of new
biomarkers.
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INTRODUCTION
Sjögren’s syndrome (SS) is a chronic autoimmune disorder, affect-
ing exocrine glands, mainly salivary and lacrimal glands, leading
to the designation of SS as an autoimmune exocrinopathy or
autoimmune epithelitis (Mavragani and Moutsopoulos, 2013).
The clinical manifestations include dry mouth (xerostomia), dry
eyes (keratoconjunctivitis sicca), and systemic features. Histologi-
cal examination shows peri-epithelial mononuclear cell inﬁltrates
in exocrine glands and parenchymal organs such as kidney, lung,
and liver. Patients with SS have a 20–40 fold increased risk
of developing lymphoma (Voulgarelis et al., 1999; Baimpa et al.,
2009; Tobon et al., 2010). Furthermore, SS is characterized by
the presence of circulating autoantibodies (Ab) against the sicca
syndrome (SS)A/Ro and SSB/La ribonucleoprotein particles (Hu
et al., 2011).
The pathogenesis of SS remains unclear. Its etiology is mul-
tifunctional and includes a combination of genetic predispo-
sitions, environmental factors, and epigenetic factors (Cobb
et al., 2008; Mavragani and Moutsopoulos, 2010; Le Dantec
et al., 2012; Liu and La Cava, 2013). Genetic factors associ-
ated with SS are particular HLA-DR allele subtypes and speciﬁc
gene polymorphisms including STAT4, IL-12A, TNIP1, IRF5,
BLK, and CXCR5 (Lessard et al., 2013). Most of these genetic
mutations are far from DNA-coding regions and they are sus-
pected to alter disease-susceptibility genes by altering their
expression indirectly via an action on the epigenetic machinery
(Dozmorov et al., 2014).
Epigenetics can be deﬁned as changes in gene expression, that
are inheritable and that donot entail changes in theDNAsequence.
Epigenetics also explains how cells can differentiate into alternative
cell types and how a phenotype can be passed from one cell to its
daughter cells (Delgado-Vega et al., 2010). Epigenetic mechanisms
are important to control the pattern of gene expression during
development, the cell cycle, and in response to biological or envi-
ronmental changes. As a consequence epigenetic dysregulations
have been linked with autoimmune diseases including SS (Brooks
et al., 2010; Renaudineau, 2010).
EPIGENETICS AND CHROMATIN
CHROMATIN
Chromatin is located in the nucleus of eukaryotic cells, and
consists of DNA, histones, transcription complexes, chromatin
modifying enzymes, and other proteins to form chromosomes.
Chromatin is divided into two forms, euchromatin and hete-
rochromatin. Euchromatin is a loosely packaged form of chro-
matin that has a high concentration of genes and is often involved
in active transcription or is at least potentiated for transcription.
In contrast, heterochromatin is a denser packaging of DNA and
proteins,which hasmany varieties. Heterochromatin is considered
to be transcriptionally inactive since the genes are less accessible
to transcription factors (Figure 1). Changes in chromatin’s struc-
ture are affected by chemical modiﬁcations of histones such as
methylation and acetylation, and by the binding of other proteins
and ions to the DNA. Most of the modiﬁcations are reversible,
providing dynamics to the chromatin structure and activity that
allows for opening of previously sequestered genes or suppression
of previously active genes in response to stimuli and cell cycle
progression.
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FIGURE 1 | Chromatin. Nucleosomes are the repetitive unit in chromatin
consisting of 145 bp of DNA wrapped around an octamer of histones.
Charges on the histones are shown as blue (positive), red (negative), and
white (neutral). The positive charges of histones facilitate binding to negatively
charged DNA and thereby packaging the DNA to reduce the overall volume
needed for the chromatin. Euchromatin is an extended form of chromatin that
allows access to the underlying genes. Heterochromatin is a condensed form
with histone H1 (orange) bound to the linker DNA between nucleosomes.
This can compact the chromatin further and sequesters the underlying genes.
The chromatin is further organized into loops that are usually tightly coiled and
stacked into chromosomes but the loops can rapidly uncoil into extended
states as depicted to allow access to sequestered genes.
HISTONES
The basic unit of chromatin is the nucleosome, a nucleoprotein
complex that consists of DNA wrapped around an octameric
core of histones (two each of histones H2A, H2B, H3, and
H4). Nucleosomes occur on average every 200 base pairs (bp)
in chromatin with 145 bp (core DNA) in close contact with
the histone core and another approximately 55 bp in the linker
section (linker DNA) between nucleosome cores. The abundance
of positively charged arginine and lysine residues in histones
are sufﬁcient to counter roughly half of the negative charges
in the core DNA, thereby reducing the self-repulsion of the
DNA and allowing a sevenfold compaction of the length held
in DNA coils around the histone core. Histones are small
globular proteins (11–15 kD) with ﬂexible N-terminal tails
that project from the nucleosome core. Epigenetic modiﬁca-
tion sites in the chromatin structure consist primarily of lysine,
arginine and serine residues in the N-terminal tails of core
histones that are post-translationally modiﬁed by acetylation,
methylation, phosphorylation, ubiquitination/sumoylation, ADP
ribosylation, deimination/citrullination, protein conjugation, or
β-N-acetylglucosamination. As a consequence, the N-terminal
tails can undergo modiﬁcations that add to or reduce the interac-
tions of the histones on neighboring histones, DNA and nuclear
proteins therefore affecting gene transcription (Huber et al., 2007;
Dieker and Muller, 2010). For example, positively charged lysine
residues can non-covalently bind to the negatively charged phos-
phate groups in the DNA but acetylation of a lysine residue
removes the positive charge and reduces the histone-DNA inter-
action. An additional histone, histone H1, can bind to the linker
DNA between nucleosomes allowing stacking of nucleosomes to
provide further compaction of the chromatin. Histone H1 is more
abundant in heterochromatin. The main histone modiﬁcations
are listed in Table 1.
Besides post-translational modiﬁcations of histones, epige-
netic control can be affected by the histone variants present
in chromatin. For example, macroH2A, a variant of the
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Table 1 | Histone modifications as part of epigenetic control.
Modification Targets Enzyme involved Effect Reversible
Acetylation Lysine Histone acetyltransferases (HATs), Histone
deacetylases (HDACs)
Acetylation removes positive charges
and reduces histone-DNA interaction
Yes
Methylation Arginine and lysine Lysine methyltransferases, arginine
methyltransferases, lysine demethylases
Methylation removes positive charges
and reduces histone-DNA interaction
Yes
Phosphorylation Serine, theonine,
tyrosine
Kinases, phosphatases Adds negative charges that can alter
chromatin structure and accessibility
Yes
Ubiquitylation/sumoylation Lysine E1, E2, E3 add 8 kD ubiquitin or 12 kD
SUMO, removal by isopetidase deubiquitin
enzymes
Suppress gene expression, possible
targeting of histone to proteosome for
degradation
Yes
ADP Ribosylation Glutamate and
arginine
Poly-ADP-ribose-polymerase (PARP),
poly-ADP-ribose-glycohydrolases
Mono-, poly-ribosylation restricts
access, possible role in chromatin
stabilization, such as in DNA repair
Yes
Deimination/citrrulination Arginine, methylated
arginine
Peptidyl arginine deiminase 4 (PAD4) Removes positive charge of arginine,
reduces histone-DNA interaction
No
Protein conjugation Lysine Transglutaminases Covalent attachment of molecules to
proteins and protein-protein
crosslinking
No
β-N- acetylglucosamine Serine, threonine O-GlcNAc transferase,
β-N -acetylglucosaminidase (O-GlcNase)
Sugar added by transferase, removed
by O-GlcNcase
Yes
Adapted from Bannister and Kouzarides (2011).
canonical H2A histone, greatly increases stability of nucleosomes,
reduces chaperone-mediated exchange of H2A–H2B dimers and
it suppresses acetylation of histones in nucleosomes (Bonisch and
Hake, 2012). The inactive X chromosome in females is kept in
a heterochromatic state due in part to a high incorporation of
macroH2A. On the other hand, other histone variants provide
epigenetic modiﬁcation sites that allow nucleosome dynamics.
The modiﬁcations can be as described above and can also include
N-terminal proteolytic sites by which the histone is irreversibly
altered to remove potential modiﬁcations and interactions of the
N-terminal tail.
DNA METHYLATION
DNA methylation is the covalent addition of a methyl group
from the methyl donor S-adenosylmethionine (SAM) to the cyto-
sine residues of CpG dinucleotides. It takes place at position 5
of the pyrimidine ring within the CpG dinucleotides. 70% of
CpG sites in human DNA are methylated in pairs, while most
of the unmethylated CpGs are situated in CpG islands. DNA
methylation is catalyzed by DNA methyltransferases (DNMTs).
DNMTs are enzymes, which transfer a methyl group to CpG
sites in DNA molecules, thereby inﬂuencing transcriptional
activity.
Three phylogenic DNMTs exist in mammals: DNMT1,
DNMT3a, and DNMT3b. DNMT1 shows a preference for
hemimethylated DNA in vitro are making it the main DNMT,
whereas DNMT3a and DNMT3b methylate unmethylated and
methylated DNA at an equal rate and serve in a de novo DNMT
role.
The insertion of a methyl group into DNA leads to struc-
tural changes of chromatin and is associated with gene silencing,
by binding methyl-CpG-binding proteins, such as MeCP2 and
MBD2, which then recruit chromatin inactivation complexes
containing histone deacetylases (HDACs) and histone methyl-
transferases (HMTs).
DNA methylation and histone modiﬁcations regulate gene
expression by modulating the packaging of the DNA inside the
nucleus. DNA methylation may also interfere with the binding of
some transcription factors.
INVOLVEMENT OF EPIGENETICS IN SS
DEMETHYLATING AGENTS AND SS
A link between demethylating drugs and SS has been known
since Cannat and Seligmann (1968) demonstrated that oral
administration of hydralazine or isoniazid to mice for several
weeks led to development of SS with immunological features
of a systemic lupus erythematosus (SLE)-like disease includ-
ing antinuclear antibody detection. This effect disappeared after
discontinuation of the drug and variations were observed depend-
ing on the animal strain, age, and sex (Cannat and Seligmann,
1968). Because of their capacity to inhibit DNMT activity and to
remove a methyl group from cytosines present in CpG islands,
hydralazine and procainamide were referred to as demethylating
agents (Taylor, 1968). Used to prevent hypertension, hydralazine
was reported to induce SS in humans (Darwaza et al., 1988; Brooks,
2010).
Following this, Richardson’s group demonstrated that
hypomethylated CD4+ T cells become autoreactive. Experiments
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with passive transfer of CD4+ T cells pretreated with either
of two distinct DNMT inhibitors, 5-aza-2′-deoxycytidine or
procainamide, intomice showed an inductionof anti-dsDNAanti-
body (Ab) production with the characteristics of a severe immune
complex glomerulonephritis (Quddus et al., 1993). Similar results
were obtained when B cells were used instead of CD4+ T cells
(Mazari et al., 2007).
HERV AS SENSOR OF DNA DEMETHYLATION
Description
Human endogenous retroviruses (HERVs) have spread, by revers-
ing the normal ﬂow of genetic information from DNA to RNA,
throughout the human genome and represent up to 7% of the
genome (Balada et al., 2009). For the most part, HERV genes con-
tain deletions, stop codons or frame shifts, such that no retroviral
protein is expressed. However, a few copies have retained their abil-
ity to generate functional protein but are normally epigenetically
suppressed.
The HERV-K and HERV-E families contain some of the most
active retroviral elements in the human genome and increase
the possibility that HERVs may have a role in human diseases
(Renaudineau et al., 2005a,b). The HERV-K family is the only
group of HERVs that can produce intact viral particles and it’s
also one of the most transcriptionally active families as its mem-
bers retain intact open reading frames (ORFs) which encode the
viral particles (Tugnet et al., 2013).
Human endogenous retroviruses are believed to play a role
in the pathophysiology of several autoimmune diseases, espe-
cially rheumatic diseases such as RA and SLE; and, in addition,
numerous reports have identiﬁed HERV elements in salivary
gland epithelial cells (SGECs) from SS patients (Le Dantec et al.,
2012; Tugnet et al., 2013). As a consequence of this expression,
retroviral antigens are produced, and antibodies (Ab) to Gag
and Env regions of HERVs have been reported in patients with
autoimmune diseases.
HERVs are overexpressed in salivary glands from SS patients
Garry et al. (1990) detected and identiﬁed human intracisternal
A-type retroviral particle (hIAP), which is an endogenous antigen
related to human immunodeﬁciency virus (HIV), in lymphoblas-
toid cells when co-cultured with homogenates of labial salivary
glands from SS patients (Garry et al., 1990; Brookes et al., 1992; La
Placa et al., 2004). At the same time, Brookes et al. (1992) men-
tioned that the human T cell lymphotropic virus (HTLV) related
endogenous sequence, HRES1, was overexpressed in the epithe-
lium of labial salivary glands obtained from patients with primary
SS (pSS). HRES1 regulation by DNA methylation was recently
provided (Garaud et al., 2009; Fali et al., 2013) Later, the HERV-
K113, and HRV-5 retroviral elements were found overexpressed
in pSS patients (Murovska et al., 2000; Moyes et al., 2005). More
recently, using a RT-PCR approach we have observed that at least
one HERV-E element was detected when testing labial salivary
glands from SS patients (Le Dantec et al., 2012).
Anti-HERV autoantibodies of HERV elements in SS
Using immunoblotting to test HIV antigen, Talal et al. (1990)
observed that 14/47 (30%) of pSS patients reacted with the HIV
p24 capsid antigen although sera from these patients were not
reactive against HIV gp41 and gp120 envelope antigens. Yamano
et al. (1997) conﬁrmed anti-HIVp24 reactivity in SS and provided,
in addition, molecular and serological arguments to exclude HIV
or HTLV1 viruses’ infections. The explanation came with Brookes
et al. (1992) who used synthetic peptides derived from HRES1
endogenous retrovirus and demonstrated that anti-HRES1 Ab,
detected in 35% of pSS patients, cross-react with the HTLV1
p19 capsid antigen. Similarly, Hishikawa et al. (1997) prepared
a recombinant p30 gag protein from HERV-E clone 4-1 and
related Western blotting experiments showed that anti-HERV 4-1
p30 gag Ab were detected in 35% of patients with pSS, whereas
no HERV 4-1 anti-p30gag antibodies were found in healthy
donors.
X CHROMOSOME IN SS
There are many disagreements about the role of the X chromo-
some in the development of SS. First of all, the correlation between
SS and the ratio of 9:1 between females and males strongly sug-
gests involvement of the X chromosome and, second, there are
numerous reports of trisomy X (47, XXX) and of a super female
phenotype (mosaic of XXXXX/XXXX/XXX/XX/XO) in female
patients with SS (Ozcelik, 2008).
Females inherit both maternal and paternal X chromosomes
whereasmen receive only thematernal X. Themajority of X-linked
genes are not sex-speciﬁc. Therefore, the majority of X-linked
genes should have equivalent expression in males and females. X
chromosome inactivation (XCI) is an epigenetic event initiated
in each cell early in development that leads to the transcriptional
silencing of one of the two X chromosomes in females. Conse-
quently, the mechanism results in equal dosage of genes in males
and females such that only one X chromosome is transcription-
ally active in both sexes with equal amounts of the products of
X-linked genes synthesized in cells (Brooks, 2010). The inactive
chromosome is referred to as Xi and the active as Xa. The choice
of which X chromosome to inactivate, the maternally derived or
the paternally derived, is a random choice made in somatic cells
early in the development of the embryo (Lessing et al., 2013).
As an example of the scale of chromatin, the eighth largest
human chromosome, the X chromosome, has 150 million bp con-
taining 1,098 genes, which is a relatively low gene density (Ross
et al., 2005). Approximately 750,000 nucleosomes are involved in
the packaging of the X chromosome. In the case of the inactive
X chromosome, roughly 85% of the genes are kept silent in order
to attain dosage compensation of X-linked genes. Besides the his-
tone modiﬁcations described above, silencing of the inactive X
chromosome exempliﬁes the use of two other major epigenetic
mechanisms to suppress genes: DNA methylation and non-coding
RNAs. DNA methylation in which a methyl group is added to
cytosine bases in a DNA strand alters the topology in the major
groove of DNA, which can mask binding sites from transcrip-
tion factors, thereby suppressing expression of the underlying
gene. RNA can also play a role in epigenetics in four differ-
ent ways: (1) as a structural RNA, such as the X inactivation
speciﬁc transcript (XIST RNA) which coats the inactive X chro-
mosome; (2) as an agent recruiting histone modifying enzymes,
such as deacetylases, to a site; (3) as a direct block to prevent
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transcription factors from initiating gene transcription; and (4)
as an agent to hybridize with nascent RNA transcripts leading to
degradation by ribonucleases that target double-stranded RNA
(Bernstein and Allis, 2005).
It is known that women are affectedmore often by autoimmune
diseases than men. In SLE, it was observed that increased DNA
demethylation of the Xi was associated with over-expression of the
X-linked CD40 ligand in CD4+ T cells puriﬁed from SLE women
(Lu et al., 2007). Recently, Belkhir et al. (2013) demonstrated that
membrane CD40L was overexpressed in ex vivo activated CD4+ T
cells from female patients with pSS. However, this overexpression
occurs through non-epigenetic regulatory mechanisms as demon-
strated when using DNA demethylating drugs and when testing
the DNA methylation status of the regulatory regions of CD40L.
This discordance between SLE and SS patients, when testingCD4+
T cells, may be interpreted in terms of cellular speciﬁcity based on
the observation that DNA demethylation affects predominantly
SGEC (see below). In addition, it is important to note that a
sexual dimorphism is not restricted to the immune cells but sex-
ual dimorphism was also reported in epithelial cells from salivary
glands (Konttinen et al., 2010).
LYMPHOMA IN SS
Patients with pSS have a higher risk of developing lymphoma, and
especially a non-Hodgkin B cell lymphoma. The pro-apoptotic
death associated protein kinase (DAP-kinase) gene is regulated by
DNA methylation and Toso et al. (2009) demonstrated that DNA
demethylation of this gene was restricted to the SS subgroup, com-
pared to the non-SS subgroup, in which the gene was aberrantly
hypermethylated. Another argument linking DNA methylation
and lymphoma predisposition in SS is related to the hypermethy-
lation of the runt-related transcription factor (RUNX1) gene in
CD4+ T cells from SS patients (Altorok et al., 2014).
Tobon et al. (2013) showed increased levels of Flt-3L in the sera
of 18 patients with pSS and previous lymphoma in contrast with
patients with pSS without lymphoma. Additionally, the analysis
of biological parameters showed that lymphocytopenia, low lev-
els of C4 and high levels of Flt-3L were associated with previous
occurrence of lymphoma (Tobon et al., 2013). An epigenetic con-
trol of FLt3-L in SGECs is suspected and experiments should be
conducted in SS patients to test this hypothesis.
DNA DEMETHYLATION IN SS
EPITHELIAL CELLS
Recently, we have reported in pSS patients, that global DNA
methylation was reduced in labial salivary glands when compar-
ing biopsy sections from pSS patients to controls, and that this
defect was conserved when SGEC were primarily cultured (Thabet
et al., 2013). At the molecular level, SGEC global DNA demethy-
lation was associated with a decrease in the methylating enzyme
DNMT1 and an increase in the demethylating partner Gadd45-
alpha. These observations support an active DNA demethylation
process in SGEC from SS patients. Furthermore, SGEC DNA
methylation levels were inversely correlated with SS severity and
B cell inﬁltration. The contribution of B cells in the demethy-
lation process was further explored in SS patients treated with
rituximab, a chimeric anti-CD20 monoclonal antibody from the
TEARS study (Devauchelle-Pensec et al., 2007; Thabet et al., 2013).
Indeed, global DNA methylation levels were higher 4 months
after B cell depletion in comparison with the minor salivary gland
biopsy obtained at the initiation of rituximab therapy, thus sug-
gesting that DNA demethylation in SGEC may be attributed in
part to the presence of inﬁltrating B cells. This hypothesis was
conﬁrmed in vitro, revealing in co-culture that B cell mediated
DNA demethylation in SGEC works through an alteration of the
Erk/DNMT1 pathway.
Treatment with 5-aza-2’-deoxycytidine results in the expres-
sion of the aquaporin 5 (AQP5) gene in the human salivary gland
ductal cell line NS-SV-DC, and to the increased ﬂuid secretion in
themurine agingmodel C57BL/6CrSkc (Motegi et al., 2005;Yama-
mura et al., 2012). Accordingly, it was proposed to treat SS patients
with DNA demethylating drugs in order to restore the abnormal
salivary ﬂux that characterized SS patients. However, AQP5 is not
repressed but overexpressed in SGEC from SS patients, in agree-
ment with the DNA demethylation status observed in these cells,
and the defect is at the protein level with an abnormal subcellular
localization as recently described (Lee et al., 2013).
Observing an increase of the bullous pemphigoid antigen 1
(BP320) protein coded by the epithelial splice variant of the
dystonin (DST) gene in acinar cells from SS patients, Gonza-
lez et al. (2011) have explored DST promoter methylation status
and observed a hypermethylation status. Further explorations are
mandatory in order to reveal whether this dichotomy is related
to an alternative promoter usage (Elliott et al., 2012) and/or
post-translational modiﬁcations.
T CELLS
A genome-wide analysis of DNA methylation in naïve CD4+
CD45RA+ T cells was recently performed in pSS patients. Among
485,000 CpG sites tested within the entire genome, 753 CpG
motifs were differentially methylated with the majority (311 genes,
75%) being demethylated. Demethylated genes in pSS patients
include lymphotoxin-α [previously known as tumor necrosis fac-
tor (TNF)-β] involved in T cell activation, genes implicated in
the type I interferon pathway, and genes encoding for membrane
water channel proteins.
Analysis of gene promoter DNA methylation status in CD4+
T cells has revealed a demethylation and overexpression of CD70
(TNSF7), and an absence of epigenetic regulation for interferon
regulatory factor (IRF)5 (Yin et al., 2010; Gestermann et al., 2012).
REGULATORY T CELLS
Lu’s group noted a DNA hypermethylation proﬁle at the forkhead
box P3 (FoxP3) promoter in pSS patients compared to healthy
controls (Sharma et al., 2009). In turn, they observed signiﬁcant
decreases in expression of FoxP3 mRNA and protein in periph-
eral CD4+ T cells isolated from pSS patients but not in healthy
controls. Such an observation is in agreement with the reports
describing a quantitative and qualitative defective FoxP3 Treg sub-
set in SS (Li et al., 2007; Alunno et al., 2013). Of note, FoxP3 Treg
frequency in labial salivary glands correlates positively with the
inﬂammation grade and risk factors for lymphoma development,
such asC3 and/orC4hypocomplementemia and cryoglobulinimia
(Christodoulou et al., 2008; Sarigul et al., 2010).
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HISTONE MODIFICATIONS IN SS
In CD4+ T cells from SLE patients, it was demonstrated that
DNA demethylation was associated with a global histone H3 and
H4 hyperacetylation, and a histone H3 dimethylation at lysine 4
(Zhou et al., 2011). In additions, such modiﬁcations were linked
with the development of speciﬁc autoantibodies as demonstrated
with the lupus-derived monoclonal antibodies BT-164 and KM-2
that recognize histone H3 trimethylated lysine 27, and histone H4
acetylated lysine 8, 12 and 16, respectively (Dieker et al., 2007; van
Bavel et al., 2011). Last but not least, HDAC inhibitors such as
trichostatine A and suberoylanilide hydroxamic acid revert his-
tone modiﬁcations and improve SLE disease without affecting
autoantibody titers (Mishra et al., 2003; Reilly et al., 2004). These
results suggest (i) that the DNA demetlylation observed in SGEC
from SS patients is associated with histone modiﬁcation, (ii) that
among anti-histones autoantibodies detected in SS some of them
target histone post-translational modiﬁcations, and (iii) that tar-
geting histonemodiﬁcationsmay be considered as a new treatment
in SS.
miRNA IN SS
DESCRIPTION
miRNAs are small non-coding and single-strand RNA of 19–
22 nucleotides in length, which regulate gene expression at the
post-transcriptional level and are important in a wide range of
physiological and pathological processes. miRNAs are generated
in the nucleus as primary miRNA transcripts by RNA polymerase
II, and are cleaved by an RNAse III enzyme, called Drosha. After,
they are transported to the cytoplasm by exportin 5 for further
processing by Dicer into mature miRNA duplexes;, they separated
into single strands at the core of the multiprotein RNA-induced
silencing complex (RISC) by argonaut proteins to generate miR-
NAs. Most miRNAs bind to the 3’ untranslated region (UTR) of
the targeted mRNAs which leads to either mRNA degradation or
translation or repression.
Dysregulation of miRNA expression is found to be associated
with the onset and progression of inﬂammatory autoimmune dis-
eases including SS. Consequently, in very recent years extensive
research has been done on miRNAs and their connection with
autoimmune diseases (Zare-Shahabadi et al., 2013).
miRNA IN MINOR SALIVARY GLANDS FROM SS PATIENTS
miRNAs have been investigated in minor salivary glands from SS
patients by different groups using different technical approaches
(Alevizos et al., 2011; Kapsogeorgou et al., 2011; Tandon et al.,
2012). From these studies it appears that miRNA expression is
differentially expressed when SS patients were compared with
controls. The predictive analysis of biologic pathways under
miRNA control suggests regulation of the neurologic pathways
controlling salivation (Alevizos et al., 2011), as well as the lack
of transcriptional regulation of the two main SS’s autoantigens
SSA/Ro and SSB/La by the miRNa let-7b which is repressed in pSS
(Kapsogeorgou et al., 2011).
miRNA IN PBMC AND EXOSOMES FROM SS PATIENTS
To date, only a few studies have been conducted on miRNAs in
peripheral blood mononuclear cells (PBMCs) from SS patients
and from SS-prone mouse models. According to Pauley’s group
(Pauley et al., 2009), both miR146a and miR155 are up-regulated
in response to the adaptive immune response in SS when test-
ing humans and mice. Authors have shown, in pSS patients, that
miR146a increases prior to disease onset in PBMCs, and dur-
ing full-blown disease in the salivary glands thus suggesting that
mir146a may be involved in early disease pathogenesis. In addition
to being present in PBMC, miRNAs are also present in exosomes
which are microvesicles secreted by a variety of cells including
lymphocytes (Gallo et al., 2012).
Mir146a plays a critical role in increasing phagocytic activ-
ity and repressing inﬂammatory cytokine production in human
monocytic THP1 cells. Mir146a is activated by NF kappa B, that
controls the TLR/INF pathway through the TNF-associated factor
6 (TRAF6), the IL-1 receptor associated kinase (IRAK1), the sig-
nal transducer and activator of transcription 1 (STAT1), and IRF5
(Pauley et al., 2011). Additionally, Zilahi et al. (2012) measured
the expression of miR146a and miR146b, and their target genes
IRAK1, IRAK4, TRAF6 in PBMCs of patients with pSS and from
healthy controls. By quantitative RT-PCR they found miR146a/b,
and the gene of TRAF6, overexpressed in pSS patients, whereas the
expression of IRAK1 was signiﬁcantly decreased. They proposed
that the TRAF6 gene contributes to the increased activation state
of the NF-κB pathway by the involvement of PKCξ existing nor-
mally in the disease, and perhaps the TRAF6 gene could be a new
biomarker of SS (Zilahi et al., 2012).
Experiments for mir155 have shown an effect on the response
of toll-like receptors (TLRs) and interleukin-1 receptors (TIRs)
that may affect the immune response. FoxP3 transcription factor,
which is detected in a subset of T cells inﬁltrating SS salivary
glands, has been shown to induce mir155 expression.
CONCLUSION
The etiology and many aspects of the pathogenesis of SS are still
unknown. Nowadays many researchers are trying to provide an
explanation based on epigenetic studies as to how epigenetic mod-
iﬁcations may inﬂuence the course of SS and affect autoreactivity
(Thabet et al., 2012). Improvements in our knowledge of epigenet-
ics give us the opportunity to ﬁnd new causes that may explain the
etiology of autoimmune diseases (Lu et al., 2010). Epigenetic stud-
ies offer us the opportunity to identify new targets with potential
impact on the prevention or progression of autoimmune diseases.
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